Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Geoffrey Thomas Gibney"'
Autor:
Judith D Goldberg, Joseph Markowitz, Jeffrey Weber, Ragini Kudchadkar, Tomas Kirchhoff, Anna Pavlick, Zeynep Eroglu, Melinda Vassallo, David M Woods, Andrew S Brohl, Nikhil I Khushalani, Alison Richards, Younchul Kim, Biwei Cao, Robert Ferguson, Kelsey R Monson, Carol M Amato, Paulo Burke, Ann Strange, Emily Monk, Geoffrey Thomas Gibney
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 11 (2022)
Background Adjuvant therapy for high-risk resected melanoma with programmed cell-death 1 blockade results in a median relapse-free survival (RFS) of 5 years. The addition of low dose ipilimumab (IPI) to a regimen of adjuvant nivolumab (NIVO) in Check
Externí odkaz:
https://doaj.org/article/1c7d034388cd4ebbbabd2100271c621e
Autor:
Nikhil I Khushalani, Melinda Vassallo, Judith D Goldberg, Zeynep Eroglu, Younchul Kim, Biwei Cao, Robert Ferguson, Kelsey R Monson, Tomas Kirchhoff, Carol M Amato, Paulo Burke, Ann Strange, Emily Monk, Geoffrey Thomas Gibney, Ragini Kudchadkar, Joseph Markowitz, Andrew S Brohl, Anna Pavlick, Alison Richards, David M Woods, Jeffrey Weber
Publikováno v:
Journal for immunotherapy of cancer. 10(11)
BackgroundAdjuvant therapy for high-risk resected melanoma with programmed cell-death 1 blockade results in a median relapse-free survival (RFS) of 5 years. The addition of low dose ipilimumab (IPI) to a regimen of adjuvant nivolumab (NIVO) in CheckM
Autor:
Gino Kim In, Aparna Nallagangula, Jacob Seung Choi, Lisa Tachiki, Matthew J Blackburn, Stephen Capone, Kathryn B Bollin, Daniel Y. Reuben, Keisuke Shirai, Sandy Zhang-Nunes, Omar Ragab, Alicia Terando, Jenny C. Hu, Han Lee, Shailender Bhatia, Sunandana Chandra, Jose Lutzky, Geoffrey Thomas Gibney
Publikováno v:
Journal for immunotherapy of cancer. 10(5)
BackgroundBasal cell carcinoma (BCC) is the most common malignancy worldwide, yet the management of patients with advanced or metastatic disease is challenging, with limited treatment options. Recently, programmed death receptor 1 (PD-1) inhibition h
Autor:
Geoffrey Thomas Gibney, Sandra J. Lee, Michael B. Atkins, Terence Z. Wong, Jennifer Guerriero, Thomas Urban Marron, Gary Irvin Cohen, Thach-Giao Truong, Richard D. Carvajal, Bradley Snyder, Michael Farwell, John M. Kirkwood, Jedd D. Wolchok
Publikováno v:
Journal of Clinical Oncology. 40:TPS9591-TPS9591
TPS9591 Background: In patients (pts) with advanced, metastatic melanoma (aMM) anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combination regimens yield durable responses, yet the optimal therapy duration remains unclear. Most prospective studies ha
Autor:
Yusra F. Shao, Yasmine Baca, Joanne Xiu, Ari M. Vanderwalde, Gino Kim In, Dave S. B. Hoon, Evidio Domingo-Musibay, Sourat Darabi, Burton Larry Eisenberg, Takami Sato, Geoffrey Thomas Gibney, Hirva Mamdani, Justin C Moser
Publikováno v:
Journal of Clinical Oncology. 40:9565-9565
9565 Background: Response to immune checkpoint inhibitors (ICI) in uveal melanoma (UM) is low. We aimed to elucidate tumor markers correlated with improved survival in ICI treated UM patients. Methods: Tumor samples of UM patients were tested at Cari
Autor:
Brian Gastman, Omid Hamid, Philippa Gail Corrie, Bartosz Chmielowski, Sajeve Samuel Thomas, Gregory A. Daniels, Evidio Domingo-Musibay, Donald P. Lawrence, Eric D. Whitman, Geoffrey Thomas Gibney, Anthony J. Olszanski, Yizhou Jiang, Audrey Kennedy, Jeff Aycock, Paul B. Robbins, John Brian Le Gall, Zachary Roberts, Robert E. Hawkins, Amod Sarnaik
Publikováno v:
Journal of Clinical Oncology. 40:TPS9594-TPS9594
TPS9594 Background: Patients (pts) with advanced (unresectable or metastatic) cutaneous melanoma and persistent disease after checkpoint inhibitor therapy have poor outcomes and limited treatment options, highlighting a significant unmet medical need
Autor:
Elizabeth Trehu, Timothy A. Yap, Courtney Hart, Justin F. Gainor, Amanda Hanson, Christopher J. Harvey, Gerald Steven Falchook, Margaret K. Callahan, Ty McClure, Russell K. Pachynski, Tanguy Y. Seiwert, Rachel McComb, Kyriakos P. Papadopoulos, Haley Laken, Geoffrey Thomas Gibney, Shivaani Kummar, Howard A. Burris, Sean Lacey, Scott S. Tykodi, Ellen Hooper, Osama E. Rahma, Patricia LoRusso
Publikováno v:
Cancer Research. 79:CT189-CT189
Background: ICOS is a costimulatory molecule upregulated on activated T cells. JTX-2011 is an ICOS agonist antibody intended to stimulate primed CD4 T effector cells. JTX-2011 was assessed in pts with advanced solid tumors as monotherapy (mono) and c
Autor:
Douglas Buckner Johnson, J. Andrew Carlson, Julia Andrea Elvin, Jo-Anne Vergilio, James Suh, Shakti Ramkissoon, Sugganth Daniel, David Fabrizio, Garrett Michael Frampton, Siraj Mahamed Ali, Alexa Betzig Schrock, Byoung Chul Cho, Geoffrey Thomas Gibney, Bartosz Chmielowski, Shridar Ganesan, Janice M. Mehnert, Vincent A. Miller, Phil Stephens, Laurie M. Gay, Jeffrey S. Ross
Publikováno v:
Journal of Clinical Oncology. 35:9536-9536
9536 Background: MM is a highly targetable malignancy, with both kinase inhibitors and immunotherapies providing meaningful survival benefit. Different subtypes of mm harbor distinct GA that suggest targeted and immunotherapy options. Methods: Compre